FORT LEE, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE:ALO) , a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted tentative approval for the company's ANDA for sertraline hydrochloride 25 mg, 50 mg, and 100 mg tablets. Alpharma's sertraline hydrochloride tablets are the AB-rated generic equivalent of Pfizer's Zoloft(R) tablets, a product indicated for several disorders, including depression. Zoloft(R) tablet sales in 2004 were approximately $3 billion.
This tentative approval was received by the company's U.S. Generic business. On October 17, 2005, the company announced that it had reached a definitive agreement to sell both its U.S. and International Generics businesses to Actavis Group.
Source: Alpharma, Inc.